Filter Results
AAN Releases Guideline: DMTs for Adults with MS
Alex Rae-Grant, MD, FAAN, FRCPC, lead author of the guideline, and Ruth Ann Marrie, MD, PhD, FRCPC, co-author of the guideline, presented findings of the guideline. The guideline was published online on Monday, April 23, 2018, in Neurology®, the medical journal of the American Academy of Neurology, and appears in the April 24 print issue. Visit the American Academy of Neurology at https://www.aan.com
Pediatric Migraine: Updates in Evidence-based Management - American Academy of Neurology
Pediatric migraines are a common referral to the neurologist. The AAN recently published updated pediatric migraine guidelines to reflect new clinical trial evidence. This video reviews the evidence-based ways to treat acute and chronic pediatric migraines as well as counseling patients on lifestyle choices to help reduce headaches.
Management of dyskinesia in Parkinson's disease
Rajesh Pahwa (University of Kansas Medical Center) discusses the management of dyskinesia in Parkinson's disease with a focus on amantadine (GOCOVRI™), the first and only FDA-approved medication for this indication.
Expert perspective on Parkinson's disease
Werner Poewe (Medical University Innsbruck, Austria), a recent welcome addition to our editorial board for European Neurological Review, shares his insights and highlights on Parkinson's disease from the American Academy of Neurology (AAN) Annual Meeting 2018.
Latest developments in the management of Parkinson's disease
Latest developments in the management of Parkinson's disease
Clinical Trials of Interest
At MD Anderson, the intent is ‘to have a clinical trial available for everybody who comes through the door,’ says its section chief, Chronic Lymphocytic Leukemia, Department of Leukemia, Division of Cancer Medicine, William G. Wierda, MD, PhD.
Connection to Other Cancers
Veda Giri, MD, director of the Jefferson Clinical Cancer Genetics Service and the Men’s Genetic Risk Clinic, Sidney Kimmel Cancer Center at Jefferson Health, sheds light on what needs greater awareness when it comes to prostate cancer.
Dramatic Survival Benefits
New therapies and how the medical community sequences these new therapies are having a dramatic impact on prostate cancer survival rates.
Greater Awareness Needed
More awareness, advocacy and resources are needed to support progress in the treatment of prostate cancer.
